Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R PMBL in the phase 1/2 open-label, multicenter CheckMate 436 study; we report safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, Pier Luigi, Santoro, Armando, Gritti, Giuseppe, Brice, Pauline, Barr, Paul M., Kuruvilla, John, Cunningham, David, Kline, Justin, Johnson, Nathalie A., Mehta-Shah, Neha, Lisano, Julie, Wen, Rachael, Akyol, Alev, Moskowitz, Alison J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500465/
https://www.ncbi.nlm.nih.gov/pubmed/37352266
http://dx.doi.org/10.1182/bloodadvances.2023010254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500465/
https://www.ncbi.nlm.nih.gov/pubmed/37352266
http://dx.doi.org/10.1182/bloodadvances.2023010254

Ejemplares similares